NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
07 oct. 2020 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were presented at the virtual 88th Annual...
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
28 sept. 2020 16h06 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at...
Esperion to Participate in Two Upcoming Virtual Investor Conferences
02 sept. 2020 08h41 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the...
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
10 août 2020 16h04 HE
|
Esperion Therapeutics, Inc.
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality...
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
03 août 2020 07h26 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
04 juin 2020 07h00 HE
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc.
10 mai 2018 12h08 HE
|
Federman & Sherwood
OKLAHOMA CITY, May 10, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on May 7, 2018, a class action lawsuit was filed in the United States District Court for the District of...
Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
07 mars 2016 08h30 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 07, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March...
SECURITIES NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important March 14, 2016 Deadline in Class Action – ESPR
04 mars 2016 15h30 HE
|
The Rosen Law Firm PA
NEW YORK, March 04, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. -- ESPR
11 févr. 2016 16h40 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Esperion Therapeutics, Inc....